Latest Insider Transactions at Surrozen, Inc. (SRZN)
This section provides a real-time view of insider transactions for Surrozen, Inc. (SRZN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Surrozen, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Surrozen, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2024
|
Yang Li Exec. Vice President, Research |
BUY
Grant, award, or other acquisition
|
Direct |
400
+3.54%
|
$2,000
$5.67 P/Share
|
|
Jun 14
2024
|
Charles O Williams CFO and COO |
BUY
Grant, award, or other acquisition
|
Direct |
400
+6.39%
|
$2,000
$5.67 P/Share
|
|
Jun 14
2024
|
Craig C Parker Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
400
+6.43%
|
$2,000
$5.67 P/Share
|
|
Apr 04
2024
|
Charles O Williams CFO and COO |
BUY
Open market or private purchase
|
Direct |
1,474
+50.0%
|
-
|
|
Apr 04
2024
|
Craig C Parker Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,474
+50.0%
|
-
|
|
Apr 04
2024
|
Column Group Iii Gp, LP |
BUY
Open market or private purchase
|
Indirect |
193,548
+23.57%
|
$2,903,220
$15.5 P/Share
|
|
Apr 04
2024
|
Tim Kutzkey |
BUY
Open market or private purchase
|
Indirect |
193,548
+23.57%
|
$2,903,220
$15.5 P/Share
|
|
Dec 15
2023
|
Yang Li Exec. Vice President, Research |
BUY
Grant, award, or other acquisition
|
Direct |
2,085
+50.0%
|
$10,425
$5.67 P/Share
|
|
Dec 15
2023
|
Charles O Williams CFO and COO |
BUY
Grant, award, or other acquisition
|
Direct |
2,085
+50.0%
|
$10,425
$5.67 P/Share
|
|
Dec 15
2023
|
Craig C Parker Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,046
+50.0%
|
$10,230
$5.67 P/Share
|
|
Jun 15
2023
|
Charles O Williams CFO and COO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+41.96%
|
$0
$0.38 P/Share
|
|
Jun 15
2023
|
Wen Chen Yeh Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,638
+39.32%
|
$0
$0.38 P/Share
|
|
Jun 15
2023
|
Craig C Parker Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+41.96%
|
$0
$0.38 P/Share
|
|
Dec 15
2022
|
Craig C Parker Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,578
+50.0%
|
$0
$0.41 P/Share
|
|
Dec 15
2022
|
Wen Chen Yeh Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,578
+4.01%
|
$0
$0.41 P/Share
|
|
Dec 15
2022
|
Charles O Williams CFO and COO |
BUY
Grant, award, or other acquisition
|
Direct |
9,578
+50.0%
|
$0
$0.41 P/Share
|
|
Dec 15
2022
|
Geertrui Vanhove Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,578
+22.81%
|
$0
$0.41 P/Share
|
|
Dec 14
2022
|
Mitchell J Md Blutt > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,382,499
-100.0%
|
-
|
|
Aug 11
2021
|
Kevin Harold Livingston |
BUY
Grant, award, or other acquisition
|
Indirect |
1,885,000
+46.75%
|
-
|
|
Aug 11
2021
|
Kevin Harold Livingston |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,451,000
-100.0%
|
-
|
|
Aug 11
2021
|
Kevin Harold Livingston |
SELL
Other acquisition or disposition
|
Indirect |
759,000
-34.34%
|
-
|
|
Aug 11
2021
|
Kevin Harold Livingston |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
434,000
-100.0%
|
-
|
|
Aug 11
2021
|
Benny Soffer |
BUY
Grant, award, or other acquisition
|
Indirect |
1,885,000
+46.75%
|
-
|
|
Aug 11
2021
|
Benny Soffer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,451,000
-100.0%
|
-
|
|
Aug 11
2021
|
Benny Soffer |
SELL
Other acquisition or disposition
|
Indirect |
759,000
-34.34%
|
-
|
|
Aug 11
2021
|
Benny Soffer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
434,000
-100.0%
|
-
|
|
Aug 11
2021
|
Christopher Haqq |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Aug 11
2021
|
Donald J Santel |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Aug 11
2021
|
Jennifer Jarrett |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Aug 11
2021
|
Life Sciences Consonance |
BUY
Grant, award, or other acquisition
|
Indirect |
1,885,000
+46.75%
|
-
|
|
Aug 11
2021
|
Life Sciences Consonance |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,451,000
-100.0%
|
-
|
|
Aug 11
2021
|
Life Sciences Consonance |
SELL
Other acquisition or disposition
|
Indirect |
759,000
-34.34%
|
-
|
|
Aug 11
2021
|
Life Sciences Consonance |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
434,000
-100.0%
|
-
|
|
Aug 11
2021
|
Mitchell J Md Blutt > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
3,497,500
+45.83%
|
-
|
|
Aug 11
2021
|
Mitchell J Md Blutt > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,000,000
-100.0%
|
-
|
|
Dec 01
2020
|
Kevin Harold Livingston |
BUY
Open market or private purchase
|
Indirect |
24,000
+5.24%
|
-
|
|
Dec 01
2020
|
Benny Soffer |
BUY
Open market or private purchase
|
Indirect |
24,000
+5.24%
|
-
|
|
Dec 01
2020
|
Life Sciences Consonance |
BUY
Open market or private purchase
|
Direct |
24,000
+5.24%
|
-
|
|
Dec 01
2020
|
Mitchell J Md Blutt > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
24,000
+5.24%
|
-
|
|
Nov 23
2020
|
Mitchell J Md Blutt > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,410,000
+50.0%
|
-
|
|
Nov 23
2020
|
Benny Soffer |
BUY
Open market or private purchase
|
Indirect |
410,000
+50.0%
|
-
|
|
Nov 23
2020
|
Life Sciences Consonance |
BUY
Open market or private purchase
|
Direct |
410,000
+50.0%
|
-
|
|
Nov 23
2020
|
Kevin Harold Livingston |
BUY
Open market or private purchase
|
Indirect |
410,000
+50.0%
|
-
|